NewAmsterdam Pharma Co N.V.
NAMS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 194 institutions reported holding it in 13F filings for Q2 2026, worth $4.13B in total; 3 superinvestors hold it, including Viking Global Investors and Maverick Capital.
Other share classesNAMSW
13F holders, Q1 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- +5 vs. Q4 2022
- Shares held
- 33.3M
- −169.9K (−0.5%) vs. Q4 2022
- Total value
- $444.9M
- +$82.6M (+22.8%) vs. Q4 2022
- New holders
- 8
- 4 more added
- Sold out
- 3
- 0 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 194 | $4.13B |
| Q1 2026 | 171 | $3.96B |
| Q4 2025 | 187 | $4.19B |
| Q3 2025 | 137 | $3.43B |
| Q2 2025 | 131 | $2.11B |
| Q1 2025 | 126 | $2.28B |
| Q4 2024 | 131 | $2.53B |
| Q3 2024 | 100 | $1.28B |
| Q2 2024 | 90 | $1.38B |
| Q1 2024 | 76 | $1.71B |
| Q4 2023 | 32 | $691.4M |
| Q3 2023 | 35 | $464.1M |
| Q2 2023 | 29 | $580.6M |
| Q1 2023 | 19 | $444.9M |
| Q4 2022 | 14 | $362.2M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 9,341,551 | $125.6M | 9.09% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 8,300,000 | $110.1M | 13.76% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 4,000,000 | $53.0M | 1.20% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 3,915,870 | $52.6M | 0.25% | +162,042+4.3% | Added |
| Deerfield Management Company, L.P. (Series C) | 2,535,723 | $33.6M | 0.75% | +55,524+2.2% | Added |
| Medicxi Ventures Management (Jersey) Ltd | 2,000,000 | $26.5M | 11.36% | 00.0% | Unchanged |
| BVF Inc | 1,521,948 | $20.5M | 0.75% | 00.0% | Unchanged |
| GMT Capital Corp | 1,083,800 | $14.4M | 0.56% | +83,800+8.4% | Added |
| Ensign Peak Advisors, Inc | 355,000 | $4.71M | 0.01% | 00.0% | Unchanged |
| Parkman Healthcare Partners LLC | 115,000 | $1.52M | 0.33% | +115,000 | New |
| Millennium Management LLC | 55,633 | $748.0K | 0.00% | +55,633 | New |
| Eversept Partners, LP | 45,856 | $608.1K | 0.05% | +45,856 | New |
| Schonfeld Strategic Advisors LLC | 30,100 | $399.1K | 0.00% | +30,100 | New |
| JPMorgan Chase & Co | 22,367 | $301.0K | 0.00% | +21,265+1,929.7% | Added |
| Geode Capital Management, LLC | 18,559 | $249.4K | 0.00% | +18,559 | New |
| Wolverine Asset Management LLC | 4,819 | $63.9K | 0.00% | +4,819 | New |
| Morgan Stanley | 503 | $6.67K | 0.00% | +503 | New |
| Atticus Wealth Management, LLC | 166 | $2.20K | 0.00% | +166 | New |
| DuPont Capital Management Corp | 1 | $13 | 0.00% | 00.0% | Unchanged |
| Janus Henderson Group PLC | 0 | $0 | 0.00% | −563,119−100.0% | Sold out |
| Alyeska Investment Group, L.P. | 0 | $0 | 0.00% | −200,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −88−100.0% | Sold out |